Antitumor efficacy of the Egyptian Scorpion Venom Androctonus Australis: in vitro and in vivo study

Abstract

Abstract Background Scorpion venom contains various biomolecules with potential therapeutic values against different diseases, including cancer. The present study was carried out to assess the antitumor efficacy of Androctonus australis crude venom using both in vitro and in vivo approaches. Methodology For in vitro assay, the cytotoxic effect of different venom concentrations was determined against HCT116, HepG2, MCF-7, and PC-3 as cancer cell lines and normal WISH cell line. The in vivo assay was carried out by the I.P. transplantation of EAC into Swiss albino female mice, followed by the I.P. injection of the venom at the sublethal dose 1/10 LD50 (0.025 mg/kg BW) compared to cisplatin (2 mg/kg BW), and both normal and EAC control groups were also included. The analysis of ascetic fluid tumor, survival study, and hematological, biochemical, antioxidant, and histopathological assays was evaluated in control and treated animal groups. Results Our in vitro results revealed that the A. australis venom had a selective promising activity against MCF-7 cells (IC50 = 19.71 μg/mL). Moreover, it was less cytotoxic on WISH cells. The in vivo data showed that A. australis venom exhibited a highly significant decrease in tumor volume, and viable tumor cell count, and increased the duration of lifespan compared to the EAC control group. The venom significantly enhanced both hematological and biochemical measurements compared to the EAC control group. Conclusion The results revealed that the A. australis venom exhibited in vitro and in vivo antitumor activities. Further venomics studies are needed to functionally characterize the active molecules from this scorpion venom and study their mode of action on cancer cells to develop them into potential anticancer agents.